<DOC>
	<DOC>NCT01575561</DOC>
	<brief_summary>This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of subjects with bipolar I disorder, who have either completed the core study D1050296 or experienced a protocol defined recurrence of a mood event in the double-blind phase of the core study D1050296</brief_summary>
	<brief_title>This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296</brief_title>
	<detailed_description>To evaluate the longer term safety of lurasidone (20, 40, 60 or 80 mg/day) in subjects with bipolar I disorder. Subjects will be initially treated with open-label lurasidone 40 mg/day (Day 1). Dose adjustment of study drug (20, 40, 60 or 80 mg /day) should occur at the regularly scheduled visits and in increments/decrements of 1 dose level.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject has agreed to participate by providing written informed consent. Subject has completed the 28 week Doubleblind Phase of Study D1050296 and all required assessments on the final study visit (Week 28, Visit 28); OR Subject has experienced a protocoldefined recurrence of any mood event during the Double blind Phase of Study D1050296 and has completed all required assessments on the final study visit; OR Subject had at least entered the Openlabel Phase of Study D1050296 when the Sponsor stopped the study and has completed all required assessments on the final study visit. Subject is judged by the Investigator to be suitable for participation in a 12 week clinical trial involving openlabel lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator. Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property. Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the Columbia Suicide Severity Rating Scale (CSSRS) at the extension baseline visit (final study visit in Study D1050296).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>